Previous studies indicated that a small population of CD34+ CML (stem/progenitor) cells are less responsive to imatinib and other TKIs, and act as a reservoir for the emergence of imatinib-resistant subclones [19], [21]–[23]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.